Literature DB >> 18329474

Extracorporeal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome.

Charles A Dietl1, Jorge A Wernly, Stuart B Pett, Said F Yassin, José P Sterling, Robert Dragan, Karen Milligan, Mark R Crowley.   

Abstract

OBJECTIVE: The purposes of this study are to evaluate the outcome of extracorporeal membrane oxygenation support in a subgroup of patients with Hantavirus cardiopulmonary syndrome who had a predicted mortality of 100% and to assess the complications associated with this treatment modality and with different cannulation techniques.
METHODS: Thirty-eight patients with severe Hantavirus cardiopulmonary syndrome were supported with extracorporeal membrane oxygenation between April 1994 and June 2006. Cannulation of the femoral vessels was performed on an emergency basis by a percutaneous approach in 15 (39.5%) and by an open technique in 23 (60.5%) patients. Duration of extracorporeal membrane oxygenation averaged 132 hours (range: 5-276 hours).
RESULTS: Complications from percutaneous cannulation occurred in 4 (26.6%) of 15 patients: retroperitoneal hematoma in 2 (13.3%) and lower extremity ischemia in 2 (13.3%) patients, which resolved after insertion of a distal perfusion cannula. Complications from open femoral cannulation occurred in 8 (34.8%) of 23 patients: severe bleeding in 7 (30.4%) patients and lower extremity ischemia in 1 (4.3%) patient who required a leg amputation. The overall survival was 60.5% (23/38 patients). Six (40%) of the 15 patients cannulated percutaneously and 9 (39.1%) of 23 patients who had open cannulation died. All survivors recovered completely and were discharged from the hospital after a mean hospital stay of 20.8 days (range: 10-39 days).
CONCLUSIONS: Almost two thirds of the patients with severe Hantavirus cardiopulmonary syndrome who were supported with extracorporeal circulation survived and recovered completely. The complications associated with both types of femoral cannulation may be attributed to the fact that all patients were in shock or in full cardiac arrest, and the procedure had to be done expeditiously. Earlier institution of extracorporeal membrane oxygenation may decrease the complication rates and improve the overall survival.

Entities:  

Mesh:

Year:  2008        PMID: 18329474     DOI: 10.1016/j.jtcvs.2007.11.020

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  15 in total

Review 1.  The Syrian hamster model of hantavirus pulmonary syndrome.

Authors:  David Safronetz; Hideki Ebihara; Heinz Feldmann; Jay W Hooper
Journal:  Antiviral Res       Date:  2012-06-15       Impact factor: 5.970

2.  Central nervous system complications following Hanta virus cardiopulmonary syndrome.

Authors:  Branko N Huisa; John E Chapin; John C Adair
Journal:  J Neurovirol       Date:  2009-04       Impact factor: 2.643

3.  A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).

Authors:  Jay W Hooper; Matthew Josleyn; John Ballantyne; Rebecca Brocato
Journal:  Vaccine       Date:  2013-07-24       Impact factor: 3.641

4.  Host mTORC1 signaling regulates andes virus replication.

Authors:  Shannon McNulty; Mike Flint; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

5.  Potential renal sequelae in survivors of hantavirus cardiopulmonary syndrome.

Authors:  Steven A Pergam; Darren W Schmidt; Robert A Nofchissey; William C Hunt; Antonia H Harford; Diane E Goade
Journal:  Am J Trop Med Hyg       Date:  2009-02       Impact factor: 2.345

6.  In vitro and in vivo activity of ribavirin against Andes virus infection.

Authors:  David Safronetz; Elaine Haddock; Friederike Feldmann; Hideki Ebihara; Heinz Feldmann
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

7.  Hantaviruses in the americas and their role as emerging pathogens.

Authors:  Brian Hjelle; Fernando Torres-Pérez
Journal:  Viruses       Date:  2010-11-25       Impact factor: 5.048

8.  Hantavirus pulmonary syndrome, United States, 1993-2009.

Authors:  Adam MacNeil; Thomas G Ksiazek; Pierre E Rollin
Journal:  Emerg Infect Dis       Date:  2011-07       Impact factor: 6.883

Review 9.  Viral hemorrhagic fevers: advancing the level of treatment.

Authors:  Giuseppe Ippolito; Heinz Feldmann; Simone Lanini; Francesco Vairo; Antonino Di Caro; Maria Rosaria Capobianchi; Emanuele Nicastri
Journal:  BMC Med       Date:  2012-03-29       Impact factor: 8.775

10.  Elevated VEGF Levels in Pulmonary Edema Fluid and PBMCs from Patients with Acute Hantavirus Pulmonary Syndrome.

Authors:  Irina Gavrilovskaya; Elena Gorbunova; Frederick Koster; Erich Mackow
Journal:  Adv Virol       Date:  2012-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.